Abstract 2169
Background
Cancer patients and their caregivers are expected to take joint responsibility with regard to reporting symptoms and seeking medical assistance e.g. by calling oncology emergency telephones or other helplines during their cancer trajectory. This responsibility may pose additional burdens on patients and caregivers when they are at home with symptoms that can be potential life threatening. Furthermore, in this vulnerable situation, the ability to handle the responsibility is compromised, which may influence safeguarding fundamentals of care needs. Therefore, the objective of this study is to explore the meaning of responsibility as it appeared in patients or caregivers calls to an oncology emergency telephone.
Methods
Qualitative description and qualitative content analysis guided a secondary analysis and interpretation of data from interviews with 12 participants calling an oncology emergency telephone.
Results
The analysis revealed two main themes. 1). To act responsibly as patient or caregivers was elaborated by: ‘Being watchful and alert’, ‘Reporting the symptoms’, and ‘Cross checking’. 2). To deal with the burden of responsibility was elaborated by the sub-themes: ‘Feeling safe in dealing with the burden of responsibility’, and ‘Being relieved from the burden of responsibility’.
Conclusions
Conclusion: The study provided essential knowledge on how patients and caregivers handle responsibility in their everyday living with a cancer disease, treated on an outpatient basis. The meaning of responsibility appeared in the informants’ capacity to act where they displayed responsibility to observe, assess and report symptoms and control prescribed treatment as well as to share or hand over the responsibility to the healthcare providers. Easing the burden of responsibility requires a person-centered approach that integrates physical, psychosocial and relational needs and bridge a potential imbalance between healthcare providers’ expectations and the patients’ or caregivers knowledge and capacity to act. For this to succeed, establishing a caring relationship between HCPs, patients and caregivers is essential.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Birgith Pedersen.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1707 - Clinical utility of precision immunoprofiling and monitoring of the tumor microenvironment using flow cytometry and CyTOF in patients with advanced NSCLC treated with atezolizumab: results from a phase II study for biomarker analysis (EPOC1702)
Presenter: Keisuke Kirita
Session: Poster Display session 3
Resources:
Abstract
3594 - Tumor mutation burden (TMB), PD-L1, IFN-γ signaling identify subgroups of patients (pts) who benefit from durvalumab (D, anti-PDL1) or D and tremelimumab (T, anti-CTLA4) treatment in urothelial bladder cancer (UC)
Presenter: Christophe Massard
Session: Poster Display session 3
Resources:
Abstract
744 - The decrease of TMB, TNB and HLA expression are the Mechanism of Drug Resistance of NSCLC to immunosuppressive PD-1/PD-l1.
Presenter: Sheng Yu
Session: Poster Display session 3
Resources:
Abstract
2350 - Eosinophilia during treatment of immune checkpoint inhibitors (ICIs) predicts succeeding onset of immune-related adverse events (irAEs)
Presenter: Rika Kizawa
Session: Poster Display session 3
Resources:
Abstract
5930 - A transcriptomic immunologic signature predicts favorable outcome in neoadjuvant chemotherapy treated triple negative breast tumors.
Presenter: Javier Pérez-peña
Session: Poster Display session 3
Resources:
Abstract
6127 - Alterations of TMB and TCR repertoires during Chemotherapy in East Asian lung cancer patients without TKI-related driver gene mutations
Presenter: Lele Song
Session: Poster Display session 3
Resources:
Abstract
1310 - Association of SCFA in gut microbiome and clinical response in solid cancer patients treated with andi-PD-1 antibody.
Presenter: Motoo Nomura
Session: Poster Display session 3
Resources:
Abstract
2286 - Extracellular matrix and tissue derived metabolites in a liquid biopsy identifies endotypes of metastatic melanoma patients with differential response to immune checkpoint inhibitor treatment
Presenter: Nicholas Willumsen
Session: Poster Display session 3
Resources:
Abstract
4107 - Pathologic scoring of pre-treatment H&E biopsies predicts overall survival in patients with metastatic clear cell renal cell carcinoma receiving nivolumab monotherapy
Presenter: Julie Stein
Session: Poster Display session 3
Resources:
Abstract
1291 - PD-L1 expression in uncommon EGFR-mutant non-small cell lung cancer and its response to immunotherapy
Presenter: Yun Fan
Session: Poster Display session 3
Resources:
Abstract